At the news
? MIXEDIMPACT 6/10 PREC14A filed Apr 17, 2026 at 16:15 ET
Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.2% year-over-year volume growth for EXPAREL and record-high gross margins. The company is entering a data-rich period with key 2026 catalysts from its pipeline. However, the annual meeting is contested, with activist investor DOMA Perpetual nominating three director candidates, challenging the board's composition and capital allocation strategy.
- EXPAREL achieved 6.2% year-over-year volume growth in 2025, with 8% growth in the second half.
- The company delivered record-high 2025 GAAP and Non-GAAP Gross Margins of 79% and 81%, respectively.
- Pacira returned $150 million to stockholders through share repurchases in 2025.
- The company is entering a data-rich period with key 2026 readouts expected for PCRX-201, ZILRETTA in shoulder OA, and iovera in spasticity.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access